Monthly administration of the LH-RH analogue decapeptyl for long-term treatment of ovarian dysfunctions and estrogen-dependent disorders.

The ovarian function of 11 patients suffering from estrogen-dependent disorders and ovarian dysfunction was suppressed by monthly administrations of an analogue of luteinizing hormone-releasing hormone (LH-RH). During the initial 11 to 18 days of treatment, the LH-RH analogue Decapeptyl was subcutaneously injected daily, followed by intramuscular administration of the peptide encapsulated in biodegradable microspheres at 30-day intervals over a 13- to 35-week period. After an initial increase on day 1 of treatment, serum levels of both LH and FSH declined, but did not reach hypogonadotropic values.

Immunoreactive insulin-like growth factor I in human follicular fluid.

Recent studies in laboratory animals suggest that insulin-like growth factor I (IGF-I) plays an important role in the regulation of granulosa cell function. The purpose of the present study was to investigate the presence of immunoreactive IGF-I in human follicular fluid (FF) and compare the levels of follicular IGF-I (64 follicles) with those detectable in serum (n = 19) in hyperstimulated cycles from 25 infertile patients. Also, the FF IGF-I levels were correlated to corresponding follicular volume (n = 62) and oocyte maturation (n = 37).

Prolactin and gonadotrophin dynamics in response to antagonists of LHRH and dopamine in ovariectomized rhesus monkeys: a dissection of their common secretion.

This experiment was designed to study the prolactin (PRL) and gonadotrophin response to an inhibitory analogue of luteinizing hormone releasing hormone (LHRH-A; ORG 30276) and a dopamine antagonist, metoclopramide (MCP), in castrated female rhesus monkeys. The LHRH-A given as an i.v.

Cyclic administration of an LHRH analogue and of progesterone in risk patients to oral contraceptives.

Fifty-five cycles of 9 patients with normogonadotropic ovarian function having risks against oral contraceptives (OCs) and intrauterine devices (IUDs) were treated for contraception with buserelin in a dosage of 300 to 450 micrograms per day i.n. from day 5 to day 26 of the cycles.